Liisa Bayko
Stock Analyst
(n/a)
# 4,647
Out of 4,655 analysts
77
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $22.48 | +55.73% | 4 | Oct 30, 2024 | |
| EDIT Editas Medicine | Maintains: In-Line | $7 → $3 | $2.91 | +3.09% | 4 | Oct 23, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $319.58 | +12.65% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $273.91 | -5.08% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.79 | -28.32% | 2 | Jun 18, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $1.08 | +85.19% | 3 | May 16, 2024 | |
| ETNB 89bio | Maintains: Outperform | $37 → $33 | $9.14 | +261.05% | 4 | May 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Outperform | $50 → $38 | $32.33 | +17.54% | 3 | May 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $438 | $471.12 | -7.03% | 17 | Apr 11, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $14 | $17.57 | -20.32% | 4 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $1.00 | +1,100.00% | 1 | Jul 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $50.99 | +56.89% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $8.43 | +18.62% | 4 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $11.32 | +59.01% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $6.74 | +270.92% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $10.95 | +466.21% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $66 → $60 | $50.76 | +18.20% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $10.15 | +244.83% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $43.82 | -45.23% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $8.28 | +262.32% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.96 | +152.53% | 1 | Feb 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.60 | - | 2 | Jun 13, 2019 |
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $22.48
Upside: +55.73%
Editas Medicine
Oct 23, 2024
Maintains: In-Line
Price Target: $7 → $3
Current: $2.91
Upside: +3.09%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $319.58
Upside: +12.65%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $273.91
Upside: -5.08%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.79
Upside: -28.32%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.08
Upside: +85.19%
89bio
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $9.14
Upside: +261.05%
Akero Therapeutics
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $32.33
Upside: +17.54%
Vertex Pharmaceuticals
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $471.12
Upside: -7.03%
Travere Therapeutics
Sep 22, 2023
Maintains: Outperform
Price Target: $30 → $14
Current: $17.57
Upside: -20.32%
Jul 6, 2023
Initiates: Outperform
Price Target: $12
Current: $1.00
Upside: +1,100.00%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $50.99
Upside: +56.89%
Apr 20, 2023
Maintains: Outperform
Price Target: $13 → $10
Current: $8.43
Upside: +18.62%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $11.32
Upside: +59.01%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $6.74
Upside: +270.92%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $10.95
Upside: +466.21%
Jun 23, 2022
Downgrades: In-Line
Price Target: $66 → $60
Current: $50.76
Upside: +18.20%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $10.15
Upside: +244.83%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $43.82
Upside: -45.23%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $8.28
Upside: +262.32%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.96
Upside: +152.53%
Jun 13, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $3.60
Upside: -